Rawinson Fernando, MD
Payments from drug & device makers
Across 25 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$86
- Supernus Pharmaceuticals, Inc.$46
- SK Life Science, Inc.$43
- Eisai Inc.$40
- Banner Life Sciences, LLC$32
- Strongbridge US Inc.$32
- plus $224 from 11 others
What the payments were for
- Food & beverage$503100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 4 | $86 |
| Supernus Pharmaceuticals, Inc. | 3 | $46 |
| SK Life Science, Inc. | 2 | $43 |
| Eisai Inc. | 2 | $40 |
| Banner Life Sciences, LLC | 1 | $32 |
| Strongbridge US Inc. | 2 | $32 |
| GE HealthCare | 1 | $32 |
| Amgen | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Abbott | 1 | $20 |
| Neurelis, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Tanabe Pharma America, Inc. | 1 | $18 |
| Biogen | 1 | $17 |
| Livanova USA, Inc. | 1 | $13 |
| Nevro Corp. | 1 | $12 |
How this compares
$503 in reported general payments places this provider in the 30th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 244 | $5,482 |
| Memantine Hcl | 101 | $3,803 |
| Carbamazepine ErCarbamazepine | 16 | $3,567 |
| DilantinPhenytoin Sodium Extended | 12 | $2,838 |
| Oxcarbazepine | 14 | $1,920 |
| Carbamazepine | 29 | $1,513 |
| Donepezil Hcl | 113 | $1,323 |
| Valproic Acid | 29 | $1,007 |
| Lamotrigine | 28 | $942 |
| Gabapentin | 57 | $923 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 27 | $563 |
| RivastigmineRivastigmine Tartrate | 16 | $502 |
| ClopidogrelClopidogrel Bisulfate | 27 | $345 |
| Ropinirole Hcl | 12 | $333 |
| Clonazepam | 12 | $88 |
Paid to pharmacies, not to this prescriber.
Other neurology in Yuma
- David WeidmanPhoenix$7.4M
- Hemant PandeyChandler$6.2M
- Stephen FlitmanPhoenix$4.4M
- Barry HendinPhoenix$4.4M
- Jeremy ShefnerPhoenix$3M
- Danielle CabralPhoenix$2.8M
- Suraj MuleyPhoenix$2.8M
- Todd SchwedtPhoenix$2.8M
- Todd LevinePhoenix$2.7M
- Nida LaurinScottsdale$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.